St Hope Foundation Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$45,554	1
2024	Research	$23,898	9
2023	Research	$78,520	20
2022	Research	$154,800	39
2021	Research	$196,661	33
2020	Research	$174,026	41
2019	Research	$152,170	32

Breakdown

Who paid Research payments · program years 2019–2025

ViiV Healthcare Company $699,170 145 payments
Regeneron Pharmaceuticals, Inc. $64,349 15 payments
Pfizer Inc. $50,546 9 payments
AbbVie, Inc. $4,600 3 payments
GlaxoSmithKline, LLC. $4,434 1 payment
Boehringer Ingelheim Pharmaceuticals, Inc. $2,230 1 payment
Merck Sharp & Dohme Corporation $300 1 payment

Studies the money was for Research payments · program years 2019–2025

PH 3 HIV Two-Year Non-Inferiority Compared to Standard of Care Safety/ $335,572 44 payments
A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority $118,671 26 payments
A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority $77,723 27 payments
A Phase 3B Multi-Center, Open Label, Single Arm, 48-Week Study, Evalua $68,998 18 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $64,349 15 payments
A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, No $63,606 15 payments
A Phase Iiib, Randomized, Multicenter, Active-Controlled, Parallel-Gro $34,600 15 payments
An Interventional Efficacy and Safety Phase 23 Doubleblind 2Arm Study to Investigate Orally Administered Pf07321332ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Increased Risk of Progressing to Severe Illness $17,648 4 payments
An Interventional Efficacy and Safety Phase 23 Doubleblind 2 Arm Study to Investigate Orally Administered PF 07321332Ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Low Risk of Progressing to Severe Illness $17,648 2 payments
A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $15,250 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.